<DOC>
	<DOCNO>NCT02008656</DOCNO>
	<brief_summary>The study design test hypothesis patient Locally advanced rectal cancer ( LARC ) treat Total neoadjuvant therapy ( TNT ) Total mesorectal excision ( TME ) Non-operative management ( NOM ) improve 3-year disease-free survival ( DFS ) compare patient similar tumor treat Chemoradiation therapy ( CRT ) , Total mesorectal excision ( TME ) Adjuvant chemotherapy ( ACT ) .</brief_summary>
	<brief_title>Trial Evaluating 3-year Disease Free Survival Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction Consolidation Chemotherapy Total Mesorectal Excision Non-operative Management</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically confirm diagnosis adenocarcinoma rectum Clinical Stage II ( T34 , N ) Stage III ( T , N+ ) base MRI Rectal tumor baseline would consider require complete TME No evidence distant metastases No prior pelvic radiation therapy No prior chemotherapy surgery rectal cancer Age ≥ 18 year The minimum legal age consent select Canadian province 19 No active infection require systemic antibiotic treatment ( oral antibiotic acceptable discretion treat physician ) ECOG Performance status 02 Women childbearing potential ( WOCBP ) negative pregnancy test ( urine blood ) agree use effective contraceptive method . A woman childbearing potential define one biologically capable become pregnant . Reliable contraception use trial screen must continue throughout study . Patients must read , agree , sign statement Informed Consent prior participation study . Patients read understand English eligible may consent accord institutional federal regulation . ANC &gt; 1.5 cells/mm3 , HGB &gt; 8.0 gm/dl , PLT &gt; 150,000/mm3 total bilirubin ≤ 1.5 x ULN ( except patient Gilbert 's Syndrome must total bilirubin ≤ 3.0 x ULN ) , AST≤ 3 x ULN , ALT ≤ 3 x ULN . Recurrent rectal cancer Primary unresectable rectal cancer . A tumor consider unresectable invade adjacent organ en block resection achieve negative margin . Creatinine level great 1.5 time upper limit normal . Patients receive prior pelvic radiotherapy . Patients unable undergo MRI . Patients history arterial thrombotic event within past 6 month . This include angina ( stable unstable ) , MI , TIA , CVA . Patients history venous thrombotic episode deep venous thrombosis , pulmonary embolus occur 6 month prior enrollment may consider protocol participation , provide stable dos anticoagulant therapy . Similarly , patient anticoagulated atrial fibrillation condition may participate , provide stable dos anticoagulant therapy . Other Anticancer Experimental Therapy . No experimental therapy ( include chemotherapy , radiation , hormonal treatment , antibody therapy , immunotherapy , gene therapy , vaccine therapy , angiogenesis inhibitor , matrix metalloprotease inhibitor , thalidomide , antiVEGF/Flk1 monoclonal antibody experimental drug ) kind permit patient receive study treatment . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period . Women pregnant breastfeeding . Patients concurrent medical psychiatric condition disease , investigator 's judgment , would make inappropriate candidate entry study . Patients history prior malignancy within past 5 year , except adequately treat basal cell squamous cell skin cancer situ cervical cancer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>CAPECITABINE ( ORAL )</keyword>
	<keyword>FLUOROURACIL</keyword>
	<keyword>LEUCOVORIN</keyword>
	<keyword>OXALIPLATIN</keyword>
	<keyword>Total mesorectal excision</keyword>
	<keyword>Chemoradiation therapy</keyword>
	<keyword>Total neoadjuvant therapy</keyword>
	<keyword>13-213</keyword>
</DOC>